Three‐Stage Evolution of China's Breakthrough Therapy Drug Policy: AI‐Driven Quantitative Evidence and Global Implications
The International Journal of Health Planning and Management · 2026-07 · 41 (4) · 753-767
DOI: 10.1002/hpm.70086 ↗Kurz gefasst
Fachartikel in der Zeitschrift The International Journal of Health Planning and Management, online erschienen am 27.05.2026. Verfasst von Mingming Zhai und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Business Administration, Shenyang Pharmaceutical University, Shenyang, China. Hauptthemen laut MEDLINE: Health Policy, Artificial Intelligence, Drug Approval. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Foundation of Liaoning Province Education Administration in China, Shenyang Pharmaceutical University Innovation and Entrepreneurship Training Program Project.
Abstract (Originalsprache)
Background
Many countries have accelerated the approval of innovative drugs through breakthrough therapy policies to meet public health needs. China needs to optimise its policy system to narrow the gap with international practices.
Objective
To identify shortcomings in China's breakthrough therapy policies and formulate optimization strategies via quantitative analysis of their dynamic evolution and cross‐jurisdictional comparisons.
Methods
Adopting a quantitative design, this study employs AI technologies (LDA topic modelling + time‐series deduction), combined with cross‐jurisdictional policy element matrix comparison and typical drug case analysis, to systematically analyse the evolutionary path and implementation effects of China's breakthrough therapy drug policies.
Results
Quantitative analysis of 59 policy texts (2020–2024) reveals that China's policies have undergone a three‐stage evolution: ‘approval‐driven (2020–2022)—collaborative transition (2023–2024)—ecological construction (exploratory scenario deduction after 2024)’. The core topics focus on ‘drug review’, ‘industrial innovation’, and ‘medical services’, among which ‘drug review’ and ‘industrial innovation’ form a dual‐dominant pattern. However, the persistently low intensity of the ‘medical services’ topic reflects an ecological imbalance of ‘accelerated approval—industrial innovation—lagging accessibility’. Cross‐jurisdictional comparisons show gaps in early innovation incentives, international collaboration, and medical support.
Conclusions
Based on the quantitative analysis of policy texts, this study proposes six optimization suggestions. These targeted strategies aim to address the imbalance of ‘fast approval but slow accessibility,’ support the ‘Healthy China 2030’ strategic goal, and provide references for developing countries in balancing resource allocation, accelerating research and development through the integration of artificial intelligence, and avoiding accessibility disparities via risk‐sharing mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Business Administration, Shenyang Pharmaceutical University, Shenyang, China.
- School of Medical Devices, Shenyang Pharmaceutical University, Shenyang, China.
- School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.
- School of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang, China.
- Institution of Regulatory Science for Medical Products, Shenyang Pharmaceutical University, Shenyang, China.
ORCID-Profile: Mingming Zhai
Förderung
- Foundation of Liaoning Province Education Administration in China
- Shenyang Pharmaceutical University Innovation and Entrepreneurship Training Program Project
Zitieren
APA
Zhai, M., Zhang, A., Li, X., Liu, X., Lu, Z., Zhan, X., & Huang, Z. (2026). Three‐Stage Evolution of China's Breakthrough Therapy Drug Policy: AI‐Driven Quantitative Evidence and Global Implications. The International Journal of Health Planning and Management, 41(4), 753-767. https://doi.org/10.1002/hpm.70086
Vancouver
Zhai M, Zhang A, Li X, Liu X, Lu Z, Zhan X, et al. Three‐Stage Evolution of China's Breakthrough Therapy Drug Policy: AI‐Driven Quantitative Evidence and Global Implications. The International Journal of Health Planning and Management. 2026;41(4):753-767. doi:10.1002/hpm.70086
BibTeX
@article{Zhai2026,
author = {Zhai, Mingming and Zhang, Aiquan and Li, Xinyu and Liu, Xiaohui and Lu, Ziyi and Zhan, Xinyuan and Huang, Zhe},
title = {Three‐Stage Evolution of China's Breakthrough Therapy Drug Policy: AI‐Driven Quantitative Evidence and Global Implications},
journal = {The International Journal of Health Planning and Management},
year = {2026},
volume = {41},
number = {4},
pages = {753--767},
doi = {10.1002/hpm.70086}
}
EUVIMED